Silybin C-23 chemical modifier with anti-tumor activity and preparation method of silybin C-23 chemical modifier

By transforming the C-23 and C-7 structures of silybin, a silybin modification with anti-tumor activity was designed, which showed significant inhibitory effects on prostate cancer and liver cancer cells, solving the existing water The problem of insufficient activity of lybin.

CN118955480APending Publication Date: 2024-11-15SHENYANG INSTITUTE OF CHEMICAL TECHNOLOGY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410964201.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing silybin has limited inhibitory activity on human prostate cancer cells and liver cancer cells, and it is necessary to develop compounds with stronger anti-tumor activity.

Method used

By transforming the C-23 and C-7 positions of silybin, a series of silybin analogs I1 to I17 were designed, including the introduction of groups such as hydroxyl, acyloxy and alkyl. The series of chemical reactions resulted in silybin modifications with anti-tumor activity.

Benefits of technology

The synthetic silybin modification has a significant inhibitory effect on human prostate cancer cells and liver cancer cells. The IC50 value is lower than that of the positive control drug gefitinib. In vitro experiments show that its anti-proliferative activity is higher than that of the original silybin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004951260430000011
    Figure BDA0004951260430000011
  • Figure BDA0004951260430000021
    Figure BDA0004951260430000021
  • Figure BDA0004951260430000022
    Figure BDA0004951260430000022
Patent Text Reader

Abstract

The invention discloses a silybin C-23 site chemical modifier with anti-tumor activity and a preparation method thereof, and relates to an anti-tumor activity modifier and a preparation method thereof. According to the invention, a series of structural analogues with antitumor activity are obtained by transforming and modifying the chemical structure of a natural product silybin. Silybin is used as a lead compound, silybin C-23-OH is subjected to selective etherification to generate 23-O-DMT-silybin, then 23-O-DMT-silybin and acetic anhydride are subjected to acylation to obtain 23-O-DMT-3, 5, 7, 20-tetra-O-acetyl-silybin ester, then I2 is used for hydrolysis and dissociation of C-23-OH, acylation and C-7 hydrolysis with different acyl chlorides are carried out, and the silybin compound is obtained. And finally, respectively introducing different acyl groups into C-7 hydroxyl groups to obtain a series of novel silybin derivatives I1-I17. Pharmacological experiment research shows that the compound has an obvious inhibition effect on human prostate cancer cells PC-3 and DU145, and the inhibition effect is better than that of silibinin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an anti-tumor activity modified substance and a preparation method thereof, in particular to a silybin C-23 chemical modified substance with anti-tumor activity and a preparation method thereof. Background Art

[0002] Silybin is a polyphenolic flavonoid extracted from the seeds of the plant milk thistle and is the main active ingredient in silymarin. [2] Silybin is a mixture of diastereoisomers Silybin A and Silybin B (1:1). Molecular formula: C 25 H 22 O 10 , molecular weight: 482.436. Melting point: 164-174℃, density: 1.527g / cm 3 . Silybin is a pure off-white crystalline powder, odorless, slightly bitter, and hygroscopic. It is easily soluble in acetone, ethyl acetate, methanol, and ethanol, slightly soluble in chloroform, and almost insoluble in water. Silybin has been used to treat a series of liver diseases. In recent years, the anti-tumor and antioxidant activities of silybin have been gradually developed and reported. Silybin has shown inhibitory effects on a variety of tumor cells, including prostate cancer cells, breast cancer cells, cervical cancer cells, colon cancer cells, and liver cancer cells.

[0003] The chemical structure of silybin:

[0004] Summary of the invention

[0005] The present invention aims to provide a C-23 chemically modified compound of silibinin with anti-tumor activity and a preparation method thereof. The method uses silibinin as a lead compound to design a series of chemically modified compounds of silibinin, and the compounds have good inhibitory activity against human prostate cancer cells (DU 145) and human liver cancer cells (PC-3).

[0006] The objective of the present invention is achieved through the following technical solutions:

[0007] A chemically modified silibinin at position C-23 with anti-tumor activity, wherein the modified silibinin is obtained by structurally modifying the hydroxyl groups at positions C-23 and C-7 to obtain a series of silibinin analogs I1 to I 17 , the silybin chemical modification is as follows:

[0008]

[0009] The C-23 hydroxyl group R is shown in the following table:

[0010]

[0011]

[0012] A method for preparing a C-23 chemically modified substance of silybin having anti-tumor activity, the method comprising the following preparation steps:

[0013] (1) The C-23-hydroxyl group of silybin is selectively etherified with DMT-Cl to obtain 23-O-DMT-silybin;

[0014] (2) 23-O-DMT-silybin is then acylated with acetic anhydride to obtain 23-O-DMT-3,5,7,20-tetra-O-acetyl-silybin ester;

[0015] (3) using I2 iodination to remove the DMT group and liberate the C-23 hydroxyl group to obtain 3,5,7,20-tetra-O-acetyl-silybin ester;

[0016] (4) 3,5,7,20-tetra-O-acetyl-silybin ester is acylated with different acyl chlorides to obtain 23-O-acyloxy-3,5,7,20-tetra-O-acetyl-silybin ester; in addition, 3,5,7,20-tetra-O-acetyl-silybin ester is alkylated with different alkyl halides to obtain 23-O-alkyl-3,5,7,20-tetra-O-acetyl-silybin ester;

[0017] (5) 23-O-acyloxy-3,5,7,20-tetra-O-acetyl-silybin ester or 23-O-alkyl-3,5,7,20-tetra-O-acetyl-silybin ester is selectively hydrolyzed with 3-aminopropanol to release the C-7 hydroxyl group to obtain 23-O-acyloxy-3,5,20-tri-O-acetyl-silybin ester or 23-O-alkyl-3,5,20-tri-O-acetyl-silybin ester;

[0018] (6) 23-O-acyloxy-3,5,20-tri-O-acetyl-silybin ester or 23-O-alkyl-3,5,20-tri-O-acetyl-silybin ester undergoes alkylation reaction with iodomethane to obtain 7-O-methyl-23-O-acyl-3,5,20-tri-O-acetyl-silybin ester derivatives (I1~I 15 ) or 7-O-methyl-23-O-alkyl-3,5,20-tri-O-acetyl-silybin ester derivatives (I 15 ~I 17 ). DETAILED DESCRIPTION

[0019] The present invention will be further described in detail below in conjunction with examples.

[0020] 1. After pre-defatting the silybum seed meal with n-hexane, use anhydrous ethanol as the extraction solvent, heat and dissolve, decolorize with activated carbon, let the filtrate stand to precipitate white crystals, and recrystallize from ethyl acetate-methanol to obtain silybin.

[0021] 2. Silybin was used as raw material and pyridine as solvent. 4,4'-dimethoxytriphenylmethane chloride (DMT-Cl) was added in a 50°C water bath and reacted for 3 hours. After the reaction was completed, 100 mL of 5% glacial hydrochloric acid was added to the reaction solution, and the solution was filtered under reduced pressure and dried to obtain 23-O-DMT-silybin (A).

[0022]

[0023] 3. After compound A is dissolved in pyridine, acetic anhydride is added, and DMAP is used as a catalyst. The reaction is monitored by TLC. After the reaction is completed, 100 mL of 5% glacial hydrochloric acid is added to the reaction solution, and the solution is filtered under reduced pressure and dried to obtain 23-O-DMT-3,5,7,20-tetra-O-acetyl-silybin (B).

[0024]

[0025] 4. The obtained compound B was dissolved in 10 mL of a mixed solvent of methanol and dichloromethane. At room temperature, the protecting group at the C-23 position was removed by iodination with I2. The reaction was monitored by TLC. After the reaction was completed, a sufficient amount of sodium thiosulfate was added to the reaction mixture to remove any unreacted I2. Subsequently, the reaction mixture was transferred to a separation funnel for extraction, dried overnight with anhydrous magnesium sulfate and anhydrous sodium sulfate, filtered under reduced pressure and dried to obtain 3,5,7,20-tetra-O-acetyl-silybin (C).

[0026]

[0027] The obtained 3,5,7,20-tetra-O-acetyl-silybin (C) was dissolved in tetrahydrofuran, and acyl chloride and triethylamine were added. The reaction was allowed to proceed at room temperature for 1 hour, and the reaction was monitored by TLC. After the reaction was completed, 100 mL of 5% glacial hydrochloric acid was added to the reaction solution, vacuum filtered, concentrated under reduced pressure and dried to obtain 23-O-acyloxy-3,5,7,20-tetra-O-acetyl-silybin (D).

[0028]

[0029] Wherein R is benzoyl, o-methylbenzoyl, n-hexanoyl, p-chlorobenzoyl, p-fluorobenzoyl, phenylacetyl, cyclohexylcarbonyl, p-trifluoromethylbenzoyl, m-chlorobenzoyl, propionyl, isobutyryl, n-butyryl, chloroacetyl, furanoyl, phenylpropionyl.

[0030]

[0031] Dissolve 23-O-acyloxy-3,5,7,20-tetra-O-acetyl-silybin (D) in pyridine and add 3-aminopropanol in an ice-water bath. The reaction was carried out for 35 seconds at room temperature, and the reaction was monitored by TLC. After the reaction was completed, glacial acetic acid was added to quench the reaction. The reaction solution was placed in 100mL of 5% glacial hydrochloric acid for recrystallization. Filter under reduced pressure and dry to obtain the synthesis of 23-O-acyloxy-3,5,20-tri-O-acetyl-silybin (E).

[0032]

[0033] 23-O-Acyloxy-3,5,20-tri-O-acetyl-silybin (E) was dissolved in N,N-dimethylformamide and CH3I was added. Potassium bicarbonate and KI were used as acid scavengers in the reaction. The reaction mixture was heated under reflux at 80°C for 2 hours. The reaction was monitored by TLC, and 100 mL of 5% glacial hydrochloric acid was added after the reaction was completed for recrystallization. 7-O-methyl-23-O-benzoyl-3,5,20-tri-O-acetyl-silybin (F,I1-I 15 ).

[0034]

[0035]

[0036] The obtained 3,5,7,20-tetra-O-acetyl-silybin (C) was dissolved in N,N-dimethylformamide (DMF, 8 mL) and alkyl halide was added. Potassium bicarbonate and KI were used as acid scavengers in the reaction. The reaction mixture was heated under reflux at 80°C for 2 hours and the reaction was monitored by TLC. After the reaction was completed, 100 mL of 5% glacial hydrochloric acid was added for recrystallization.

[0037] Filtration under reduced pressure and drying were performed to obtain 23-O-alkyl-3,5,7,20-tri-O-acetyl-silybin (G).

[0038]

[0039] Wherein R is benzyl or methyl.

[0040]

[0041] Repeat steps

[0012] and

[0013] to obtain 7-O-methyl-23-O-alkyl-3,5,20-tri-O-acetyl-silybin (H,I 16 -I17 ).

[0042] Using Gefitinib as a positive control, the MTT method was used to conduct preliminary in vitro anti-tumor activity tests on silybin and its synthesized compounds. The study showed that the synthesized compounds had a certain inhibitory effect on human prostate cancer cells (PC-3) and (DU 145). The compound structures and in vitro experimental results are shown in the following table:

[0043]

[0044]

[0045] Note: a. Inhibition rate measured at a compound concentration of 10 μM. b. IC 50 It indicates the half effective inhibitory concentration.

[0046] The anti-tumor activity of the target compound was tested by MTT method. Gefitinib was used as a positive control. The results showed that the anti-proliferative activity of the target compound against human prostate cancer cells PC-3 and DU 145 was higher than that of the lead compound silibinin, and I2 and I8 were comparable to the positive control drug gefitinib. In vitro anti-tumor experiments showed that the introduction of methoxy at the C-7 hydroxyl group and aryl and halogen atoms at the C-23 hydroxyl group enhanced the anti-proliferative activity of silibinin.

[0047] Here are some examples:

[0048] Example 1

[0049] Synthesis of 23-O-DMT-3,5,7,20-Tetra-O-acetyl-silybin Ester

[0050] Silybin (S, 0.241 g, 0.5 mmol) was dissolved in THF and evaporated several times at 50 °C.

[0051] Anhydrous pyridine (5mL) was added with 4,4'-dimethoxytriphenylmethane chloride (DMT-Cl, 0.440g, 1.3mmol) and reacted at 50°C for 3h. The reaction was used to protect the hydroxyl group at the C-23 position of silybin. After the reaction was completed by TLC monitoring, the reaction solution was added to a stirred 5% hydrochloric acid solution (100mL) and the product 23-O-DMT-silybin was obtained by vacuum filtration. Subsequently, 23-O-DMT-silybin (0.392g, 0.5mmol) was dissolved in pyridine and acetic anhydride was added to initiate the esterification reaction. DMAP was used as a catalyst to speed up the reaction time. After the reaction was completed by TLC monitoring, the reaction solution was added to a stirred 5% hydrochloric acid solution (100 mL), and vacuum filtered to obtain a dry white solid product 23-O-DMT-3,5,7,20-tetra-O-acetyl-silybin ester with a yield of 96.8% (0.461 g, 0.48 mmol). mp 143.2~145.6℃.

[0052] Example 2

[0053] Synthesis of 3,5,7,20-Tetra-O-acetyl-silybin Ester

[0054] 23-O-DMT-3,5,7,20-tetra-O-acetyl-silybin ester (0.476 g, 0.5 mmol) was dissolved in 10 mL of a mixed solvent of methanol and dichloromethane. The protective group at the C-23 position was removed by iodination using I2 (355 mg, 0.7 mmol), and good reaction results were obtained at room temperature. The progress of the experiment was monitored by thin layer chromatography (TLC). When the reaction reached its endpoint, a sufficient amount of sodium thiosulfate was added to the reaction mixture to remove any unreacted I2. Subsequently, the reaction mixture was transferred to a separation funnel for extraction, and 5% glacial hydrochloric acid and dichloromethane were used as the aqueous phase and organic phase, respectively. It was then dried overnight with anhydrous magnesium sulfate and anhydrous sodium sulfate, followed by vacuum filtration and reduced pressure concentration. Recrystallization from methanol gave 3,5,7,20-tetra-O-acetyl-silybin ester (0.304 g, 0.47 mmol) as a pink solid in a yield of 93.6%. mp127.5~130.7℃.

[0055] Example 3

[0056] Synthesis of 23-O-benzoyl-3,5,7,20-tetra-O-acetyl-silybin ester

[0057] 3,5,7,20-Tetra-O-acetyl-silybin ester (0.325 g, 0.5 mmol) was dissolved in THF (10 mL), and then benzoyl chloride (0.6 mmol) and triethylamine (140 l, 1 mmol) were added. The reaction was allowed to proceed at room temperature for 1 hour and monitored by thin layer chromatography (TLC). After the reaction was completed, vacuum filtration was performed and the mixture was concentrated under reduced pressure. Finally, the white solid product, 23-O-benzoyl-3,5,7,20-tetra-O-acetyl-silybin ester (0.363 g, 0.480 mmol), was obtained by recrystallization with a yield of 96.11%. mp130.9~132.4℃.

[0058] Example 4

[0059] Synthesis of 23-O-benzoyl-3,5,20-tri-O-acetyl-silybin ester

[0060] 23-O-benzoyl-3,5,7,20-tetra-O-acetyl-silybin ester (0.377 g, 0.5 mmol) was dissolved in pyridine, and 3-aminopropanol (115 L, 1.5 mmol) was added under an ice-water bath. The reaction was allowed to proceed for 35 seconds, and the reaction was rapidly quenched by adding glacial acetic acid. The reaction was monitored using thin layer chromatography (TLC). After the reaction was completed, the reaction solution was placed in 5% glacial hydrochloric acid for recrystallization. Finally, 23-O-benzoyl-3,5,20-tri-O-acetyl-silybin ester (0.345 g, 0.484 mmol) was obtained by vacuum filtration in a yield of 96.9%. mp137.6~139.1℃.

[0061] Example 5

[0062] Compound I1: Synthesis of 7-O-methyl-23-O-acyl-3,5,20-tri-O-acetyl-silybin ester

[0063] 23-O-Acyl-3,5,20-tri-O-acetyl-silybin ester (0.326 g, 0.5 mmol) was dissolved in N,N-dimethylformamide (DMF, 8 mL), and then CH3I (93.29 L, 1.5 mmol, 3 equiv) was added. Potassium bicarbonate (1.5 mmol, 3 equiv) and KI (5 mg) were used as acid scavengers in the reaction. The reaction mixture was then heated under reflux at 80°C for 2 hours. After the reaction was completed, 100 mL of 5% glacial hydrochloric acid was added, which was monitored by a thin layer chromatography plate. Finally, 7-O-methyl-23-O-acyl-3,5,20-tri-O-acetyl-silybin ester (0.312 g, 0.430 mmol) was obtained by vacuum filtration in a yield of 85.9%. mp 113.5~117.6°C. 1H-NMR (400MHz, DMSO-d6) δ8.12(d,J=6.9Hz,2H),7.77(t,J=7.4Hz,1H),7.62(t,J =7.7Hz,2H),7.26–6.97(m,8H),6.01(t,J=12.0Hz,1H),5.72(d,J=12.3Hz,1H),5.1 2(t,J=7.9Hz,1H),4.67–4.60(m),4.14(d,J=10.9Hz,1H),3.97(dd,J=12.4,5.0Hz ,1H),3.79(s,3H,OCH3),3.62(s,3H,OCH3),2.31(s,3H),2.26(s,3H),2.01(s,3H).

[0064] Example 6

[0065] Compound I16: Synthesis of 7-O-methyl-23-O-benzyl-3,5,20-tri-O-acetyl-silybin

[0066] 3,5,7,20-Tetra-O-acetyl-silybin ester (0.3265 g, 0.5 mmol) was dissolved in N,N-dimethylformamide (DMF, 8 mL), and then benzyl bromide (178.33 L, 1.5 mmol, 3 equiv) was added. Potassium bicarbonate (1.5 mmol, 3 equiv) and KI (5 mg) were used as acid scavengers in the reaction. The reaction mixture was heated under reflux at 80 °C for 2 hours. After the reaction was completed by monitoring with a thin layer chromatography plate, 100 mL of 5% glacial hydrochloric acid was added. Finally, a light pink solid was obtained by vacuum filtration, and then, according to the experimental steps of I1-S-4 to I1-S-5, the product 7-O-methyl-23-O-benzyl-3,5,20,-tri-O-acetyl-silybin (0.308 g, 0.432 mmol) was finally obtained with a yield of 86.35%. mp133.3~134.6.1℃.1H-NMR (400MHz, DMSO-d6): δ7.45–7.34(m,5H),7.28–7.22(m,2H),7.15(dd,J=8.1,3.0 Hz,1H),7.10–7.02(m,3H),6.67(d,d,J=2.4Hz,1H),6.57(d,J=2.4Hz,1H),5.85(t,J=12.2Hz,1H),5.58(d, J=12.3Hz,1H),5.21(s,2H),5.12(t,J=8.1Hz,1H),4.68–4.57(m,1H),4.14(d,J=12.2Hz,1H),3.98(dd,J=1 2.4,5.0Hz,1H),3.79(s,3H,OCH3),3.77(s,3H,OCH3),2.28(s,3H,CH3),2.27(s,3H,CH3),2.01(s,3H,CH3).

Claims

1. A chemically modified product of silybin at position C-23 having anti-tumor activity, characterized in that: The modified product is a structural modification of the hydroxyl groups at the C-23 and C-7 positions to obtain a series of silybin analogs I1 to I 17 , the silybin chemical modification is as follows: The C-23 hydroxyl group R is shown in the following table:

2. A method for preparing a C-23 chemically modified product of silybin with anti-tumor activity, characterized in that: The method comprises the following preparation steps: (1) The C-23-hydroxyl group of silybin is selectively etherified with DMT-Cl to obtain 23-O-DMT-silybin; (2) 23-O-DMT-silybin is then acylated with acetic anhydride to obtain 23-O-DMT-3,5,7,20-tetra-O-acetyl-silybin ester; (3) using I2 iodination to remove the DMT group and liberate the C-23 hydroxyl group to obtain 3,5,7,20-tetra-O-acetyl-silybin ester; (4) 3,5,7,20-tetra-O-acetyl-silybin ester is acylated with different acyl chlorides to obtain 23-O-acyloxy-3,5,7,20-tetra-O-acetyl-silybin ester; in addition, 3,5,7,20-tetra-O-acetyl-silybin ester is alkylated with different alkyl halides to obtain 23-O-alkyl-3,5,7,20-tetra-O-acetyl-silybin ester; (5) 23-O-acyloxy-3,5,7,20-tetra-O-acetyl-silybin ester or 23-O-alkyl-3,5,7,20-tetra-O-acetyl-silybin ester is selectively hydrolyzed with 3-aminopropanol to release the C-7 hydroxyl group to obtain 23-O-acyloxy-3,5,20-tri-O-acetyl-silybin ester or 23-O-alkyl-3,5,20-tri-O-acetyl-silybin ester; (6) 23-O-acyloxy-3,5,20-tri-O-acetyl-silybin ester or 23-O-alkyl-3,5,20-tri-O-acetyl-silybin ester undergoes alkylation reaction with iodomethane to obtain 7-O-methyl-23-O-acyl-3,5,20-tri-O-acetyl-silybin ester derivatives (I1~I 15 ) or 7-O-methyl-23-O-alkyl-3,5,20-tri-O-acetyl-silybin ester derivatives (I 15 ~I 17 ).